CONTEXT: A very brief update, but a potentially very important one. The FDA is convening the paediatric subcommittee to discuss how to effectively use PROs in oncology studies. We will Continue Reading
CONTEXT: Commercial announcement of a RWE tie-up between C-Path Institute and Tufts. IMPACT: Low READ TIME: 1 min Quality Level Mean [1 – 10]: 5 1. “”This will significantly add Continue Reading
CONTEXT: Real-world study from Japan showing increased rates of pneumonitis with first-line pembrolizumab plus chemotherapy in patients with advanced NSCLC. IMPACT: Medium READ TIME: 2 mins Quality Level Mean [1 Continue Reading
CONTEXT: The term “Synthetic data” may not fill you with confidence, but it’s a phrase we will be seeing a lot more of in the future as organisations explore how Continue Reading
CONTEXT: Let the computer clean up your database? Well, that sounds scarier than “Synthetic Data”, but this author remembers when we used to write things down in a 3-part NCR Continue Reading
CONTEXT: Despite the headline news that RWE shows no real improvement for mesothelioma patients, if you get down to the end of the article, there is promising news with the Continue Reading
CONTEXT: Increased backing for the post-COVID era decentralised clinical trials. Can’t help thinking that this feels like a dot com bubble that will burst when the first major safety concerns Continue Reading
CONTEXT: Peer reviewed paper on Real-World treatment patterns in chronic obstructive pulmonary disease (COPD) | UK general practice data only IMPACT: Medium READ TIME: 6 mins Quality Level Mean [1 Continue Reading
CONTEXT: Not exactly a shock, but a very welcome story nonetheless. Pfizer COVID vaccine works and works well. So does the system that developed it, proved it was safe to Continue Reading
CONTEXT: EMA and DG SANTE have signed a confidentiality agreement with ANVISA | Announcement of a new partnership between EU and Brazilian Regulatory Authorities to further develop mutual recognition and Continue Reading
